Cory Watson Crowder & DeGaris has filed numerous lawsuits over the drug Trasylol. The drug is manufactured by Bayer AG, and it is used to prevent excessive bleeding during coronary artery bypass graft surgery. According to the Birmingham News, the lawsuits involve allegations over individuals who have suffered permanent kidney damage after being given the drug.
Apparently, the FDA suspended the marketing of Trasylol in November, 2007. However, 60 Minutes will report that “22,000 additional lives could have been saved if the FDA had taken action to remove the drug from the market in 2006.” Brian Turner, an attorney at Cory Watson Crowder & DeGaris, is quoted as saying, “[t]his drug, which most patients never knew they received during their surgery has caused significant injuries and loss of life due to severe and possibly life-threatening kidney problems.”
These types of cases are difficult due to the balance between attempts to improve medical care and putting dangerous drugs on the market without adequate testing. The inherent problem is the fact that drug makers are in business to make a profit, and they are competing with other drug makers. Consequently, they race to get drugs to market for fear that their competitors will beat them. The “side effects” of such competition can be dangerous drugs on the market before they are adequately tested. These types of lawsuits make such companies reassess what is important: racing to get the drug to market to make a profit or making sure it is safe for the public. Which would you say is more important?
If you would like more information on this or think you might have a potential claim, please contact our firm at email@example.com or (888) 295-7409.